Capital World Investors Reports New 5.1% Stake in CRISPR Therapeutics AG

On May 14, 2026, Capital World Investors (CWI) filed a Schedule 13G with the SEC, reporting a new 5.1% ownership stake in CRISPR Therapeutics AG (CRSP). As of the event date of March 31, 2026, CWI beneficially owns 4,929,428 shares of common stock. The filing indicates that CWI has sole dispositive power over all 4,929,428 shares and sole voting power over 4,897,705 shares. Capital World Investors is a division of Capital Research and Management Company (CRMC), and the shares are held through various investment management subsidiaries and affiliates under the CWI name. This position represents a significant increase from a previously reported 0.0% ownership, crossing the 5% disclosure threshold. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This move positions CWI as a major institutional shareholder in the gene-editing biotechnology firm.